PepGen Inc. (PEPG): Submission of Matters to a Vote of Security Holders

PepGen Inc. (PEPG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001835597 0001835597 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18,

Original reporting
Published Jun 22, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PEPG
Neutral
high confidence
Mentioned
$PEPG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PEPGNeutralLow
01

Why it matters

The disclosure confirms the election of three Class I directors and ratification of KPMG LLP as independent auditor for the fiscal year ending December 31, 2026; it does not provide new operating or financial guidance.

02

Market read

Traders may note governance continuity, but there is no new catalyst for earnings, trials, financing, or M&A in the text.

03

What to watch

The filing does not include vote margins, director performance context, or any new corporate actions beyond standard meeting results.

Relevance 6/10Novelty 2/10Timing: after-hours/filing date (June 22, 2026) following June 18 annual meeting

Background

This is an SEC Form 8-K (Item 5.07) reporting matters submitted to stockholders at PepGen’s June 18, 2026 annual meeting.

Company-level read

Ticker impact

$PEPGNeutralHigh confidence
Context

PepGen disclosed 2026 annual meeting voting results, including director elections and ratification of KPMG as auditor for 2026.

Expected impact

Low likelihood of a sustained price move solely from this 8-K voting disclosure.

Evidence & confidence

The 8-K reports routine outcomes (board election and auditor ratification) without new financial guidance, transactions, or regulatory actions.

Market effects

Minimal; governance/auditor ratification does not change biotech sector risk or competitive dynamics.

Minimal; no broader market or regional policy/regulatory signal is included.

Minimal; no international deal, trial, or regulatory development is disclosed.

Counterpoint

If investors were concerned about governance or auditor continuity, the ratification could reduce uncertainty, but the effect is usually small.

Key entities

  • PepGen Inc.

    Subject of the 8-K; reported annual meeting voting outcomes and auditor ratification.

  • KPMG LLP

    Ratified as PepGen’s independent registered public accounting firm for FY ending Dec. 31, 2026.

Related articles

$PEPGHighAI 9/10

Why is PepGen stock surging today?

PepGen's stock surged 125.1% in pre-market trading after reporting positive Phase 2 trial results for PGN-EDODM1, showing significant efficacy in treating myotonic dystrophy type 1. The company also reported $104.8M in cash for operations into 2028. CEO James McArthur expressed confidence in the asset's potential. The S&P 500 and Dow Jones rose slightly, while the Nasdaq dipped ahead of the October CPI report.

$PEPGHigh

PepGen Reports Third Quarter 2026 Financial Results

PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights – Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – – 12.5 mg/kg FREEDOM2-DM1 cohort fully enro

$PEPGMedAI 8/10

PepGen reports splicing correction results in DM1 trial

PepGen Inc. (PEPG) reported Phase 2 trial results for PGN-EDODM1 in myotonic dystrophy type 1 patients. The 10 mg/kg cohort showed 46.5% mean splicing correction, with improvements in myotonia, grip strength, and mobility tests. No severe adverse events were reported. The 12.5 mg/kg cohort is fully enrolled, with results expected in 2027.

$PEPGMedAI 8/10

PepGen (PEPG) Reports Positive Phase 2 Results at 10 mg/kg

PepGen (PEPG) reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial. The 12.5 mg/kg cohort is fully enrolled, but no specific efficacy or safety data were provided. The company's PGN-EDODM1 program is in early clinical stages, and further updates may impact investor sentiment.